Linezolid Krka (Linezolid)

Linezolid is indicated for infections caused by Gram‑positive bacteria, particularly resistant strains.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infection: effective in achieving clinical cure and bacterial eradication.
• Vancomycin‑resistant Enterococcus (VRE) infection: provides an alternative therapeutic option when other agents fail.
• Skin and soft‑tissue infections: reduces infection severity and promotes healing.
• Community‑acquired pneumonia: improves respiratory outcomes in patients with susceptible pathogens.
• Hospital‑acquired pneumonia: contributes to resolution of pulmonary infection caused by resistant Gram‑positive organisms.

• Linezolid exerts its antibacterial activity by binding to the 50S subunit of bacterial ribosomes. This interaction prevents the formation of the initiation complex required for protein synthesis, thereby inhibiting bacterial growth. The binding is reversible and selective for bacterial ribosomes, sparing mammalian protein synthesis and resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools during treatment.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Thrombocytopenia: marked decrease in platelet count.
• Peripheral neuropathy: tingling, numbness, or pain in extremities.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic drugs.
• Lactic acidosis: rare metabolic acidosis requiring immediate medical attention.

When prescribing Linezolid, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust monitoring as accumulation may occur.
• Hepatic dysfunction: evaluate liver function before initiating therapy.
• Hematologic disorders: monitor complete blood count for thrombocytopenia or anemia.
• Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome.
• Pregnancy and lactation: use only if potential benefit outweighs risk.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Linezolid interacts with several medicines; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome.
• Tyramine‑containing foods and sympathomimetic agents: can cause hypertensive reactions.

Moderate Interactions (Monitor Closely)

• Rifampin: induces metabolism, reducing linezolid plasma levels.
• Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring.
• Ethanol: may increase risk of disulfiram‑like reaction.